Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer Res. 2009 Sep 8;69(18):7243–7251. doi: 10.1158/0008-5472.CAN-09-0167

Figure 6.

Figure 6

VEGF- and SDF1-blocking experiments in mice with CSC-low and CSC-high tumors. A and B, image quantification of microvessel density in tumors ± DC101 (anti-VEGFR2) or AMD3100: number of CD31+ structures per field (counted manually). Five mice per group, eight fields per tumor. C, quantification of vessel-associated, bone marrow–derived (GFP+) endothelial cells (CD31+/VEGFR2+/CD45) ± AMD3100 per 10,000 tumor cells by flow cytometry. Five mice per group, except CSC-low control (n = 3).

HHS Vulnerability Disclosure